Quarterly report · Q1
7776.TEDINET S100TFKG
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥34m | 2024-01-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥190m | 2023-01-01 → 2023-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥31m | 2023-01-01 → 2023-03-31 | Standalone | Net sales |
| Operating income | −¥233m | 2024-01-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | −¥182m | 2023-01-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | −¥231m | 2024-01-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥710m | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥184m | 2023-01-01 → 2023-03-31 | Standalone | Ordinary income |
| Profit before tax | −¥229m | 2024-01-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥184m | 2023-01-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | −¥230m | 2024-01-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥847m | 2023-01-01 → 2023-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥184m | 2023-01-01 → 2023-03-31 | Standalone | Profit loss |
| Total assets | ¥2.4bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2023-03-31 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥291m | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥301m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.1bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.6bn | at 2023-03-31 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-7.24 | 2024-01-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-29.43 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.81 | 2023-01-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 86.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.9% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 32,172,719 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 31,459,019 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 27,659,419 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-03-31 | −¥55m |
| jpcrp040300-q1r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥387,000 |
| jpcrp040300-q1r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥387,000 |
| jpcrp040300-q1r_E24158-000Cell Sheet Regenerative Medicinereportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥164m |
| jpcrp040300-q1r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥34m |
| jpcrp040300-q1r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥34m |
| jpcrp040300-q1r_E24158-000Laboratory Consumable Equipmentreportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥13m |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥34m |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥34m |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | −¥177m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥54m |
| jpcrp040300-q1r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥249,000 |
| jpcrp040300-q1r_E24158-000Cell Sheet Regenerative Medicinereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥249,000 |
| jpcrp040300-q1r_E24158-000Cell Sheet Regenerative Medicinereportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥115m |
| jpcrp040300-q1r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥30m |
| jpcrp040300-q1r_E24158-000Laboratory Consumable Equipmentreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥30m |
| jpcrp040300-q1r_E24158-000Laboratory Consumable Equipmentreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥13m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥31m |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥31m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | −¥128m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 298
| Item | Context | Value | Unit |
|---|---|---|---|
| Foreign exchange losses noe | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Non operating expenses | Prior1YTDDuration_NonConsolidatedMember | 2686000 | JPY |
| Non operating expenses | CurrentYTDDuration_NonConsolidatedMember | 1040000 | JPY |
| Ordinary income | Prior1YTDDuration_NonConsolidatedMember | -184365000 | JPY |
| Ordinary income | CurrentYTDDuration_NonConsolidatedMember | -231484000 | JPY |
| Gain on reversal of subscription rights to shares ei | Prior1YTDDuration_NonConsolidatedMember | 609000 | JPY |
| Gain on reversal of subscription rights to shares ei | CurrentYTDDuration_NonConsolidatedMember | 2055000 | JPY |
| Extraordinary income | Prior1YTDDuration_NonConsolidatedMember | 609000 | JPY |
| Extraordinary income | CurrentYTDDuration_NonConsolidatedMember | 2055000 | JPY |
| Income before income taxes | Prior1YTDDuration_NonConsolidatedMember | -183755000 | JPY |
| Income before income taxes | CurrentYTDDuration_NonConsolidatedMember | -229428000 | JPY |
| Income taxes current | Prior1YTDDuration_NonConsolidatedMember | 237000 | JPY |
| Income taxes current | CurrentYTDDuration_NonConsolidatedMember | 237000 | JPY |
| Income taxes | Prior1YTDDuration_NonConsolidatedMember | 237000 | JPY |
| Income taxes | CurrentYTDDuration_NonConsolidatedMember | 237000 | JPY |
| Profit loss | Prior1YTDDuration_NonConsolidatedMember | -183993000 | JPY |
| Profit loss | CurrentYTDDuration_NonConsolidatedMember | -229665000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | 30446000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | 249000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 30696000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember | 30696000 | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | 30446000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | 249000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 30696000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember | 30696000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | -13364000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | -114667000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | -128032000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | -53667000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember | -181700000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | 33851000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | 387000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 34238000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember | 34238000 | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000LaboratoryConsumableEquipmentReportableSegmentsMember | 33851000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q1r_E24158-000CellSheetRegenerativeMedicineReportableSegmentsMember | 387000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 34238000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |